Stórustovu Signe I, Ebert Bjarke
Department of Electrophysiology, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Valby, Denmark.
J Pharmacol Exp Ther. 2006 Mar;316(3):1351-9. doi: 10.1124/jpet.105.092403. Epub 2005 Nov 4.
Several groups have characterized the pharmacology of alpha4- or alpha6beta3delta-containing GABA(A) receptors expressed in different cell systems. We have previously demonstrated that the pharmacological profiles of a series of GABA(A) receptor agonists are highly dependent on the alpha subunit and little on the beta and gamma subunits, so to further understand the contribution of the different subunits in the GABA(A) receptor complex, we characterized a series of full agonists, partial agonists, and antagonists at alpha4beta3, alpha4beta3delta, and alpha6beta3delta receptors expressed in Xenopus oocytes. Little or no difference was seen when the compounds were compared at alphabeta- and alphabetadelta-containing receptors, whereas a significant reduction in both potency and relative efficacy was observed compared with alphabetagamma-containing receptors described in the literature. These data clearly confirm that the presence of the delta subunit in heterotrimeric receptors is a strong determinant of the increased pharmacological activity of compounds with agonist activity. The very similar agonist pharmacology of alphabeta- and alphabetadelta-containing receptors, which is significantly different from that of alphabetagamma-containing receptors, shows that whereas the presence of a gamma subunit impairs the response to an agonist stimulation of the alphabeta receptor complex, the delta subunit does not affect this in any way. Taken together, these data are well in line with the idea that alpha4beta3delta may contribute to the pharmacological action of exogenously applied agonists and may explain why systemically active compounds such as gaboxadol and muscimol in vivo appear to act as selective extrasynaptic GABA(A) agonists.
多个研究小组已对在不同细胞系统中表达的含α4或α6β3δ的GABA(A)受体的药理学特性进行了表征。我们之前已经证明,一系列GABA(A)受体激动剂的药理学特征高度依赖于α亚基,而对β和γ亚基的依赖性较小。因此,为了进一步了解不同亚基在GABA(A)受体复合物中的作用,我们对非洲爪蟾卵母细胞中表达的α4β3、α4β3δ和α6β3δ受体的一系列完全激动剂、部分激动剂和拮抗剂进行了表征。当在含αβ和含αβδ的受体上比较这些化合物时,几乎没有观察到差异,而与文献中描述的含αβγ的受体相比,效力和相对效能均显著降低。这些数据清楚地证实,异源三聚体受体中δ亚基的存在是具有激动剂活性的化合物药理活性增加的一个重要决定因素。含αβ和含αβδ的受体具有非常相似的激动剂药理学特性,这与含αβγ的受体显著不同,这表明虽然γ亚基的存在会损害αβ受体复合物对激动剂刺激的反应,但δ亚基不会以任何方式影响这一反应。综上所述,这些数据与α4β3δ可能有助于外源性应用激动剂的药理作用这一观点非常一致,并且可以解释为什么体内具有全身活性的化合物如加波沙朵和蝇蕈醇似乎表现为选择性突触外GABA(A)激动剂。